Eli Lilly's Mounjaro retains top spot in GLP-1 drug sales May - Pharmatrac
This story was originally published at 12:59 IST on 8 June 2026
Register to read our real-time news.Informist, Monday, Jun. 8, 2026
Please click here to read all liners published on this story
--Pharmatrac: Anti-obesity mkt currently valued at INR 20 bln till May
--CONTEXT: Comments by Pharmatrac's analysts at the webinar
--Pharmatrac: Anti-obesity mkt growth down in May vs Apr, up in value terms
--Pharmatrac: Semaglutide driving growth of glucagon-like peptide-1 market
--Pharmatrac: Affordability driving growth in Semaglutide sales
--Pharmatrac: Indian GLP-1 market is moving beyond generic launch-led growth
--Pharmatrac: Semaglutide generic growth appears to be stabilising
--Pharmatrac: Sustained GLP-1 demand needs expansion of eligible patient pool
--Pharmatrac: GLP-1 Innovator brands resilient despite generic competition
--Pharmatrac:Mounjaro maintains 1st position for sales in May, Augmentin 2nd
--Pharmatrac: India's pharma market showed 11% value growth in May
--Pharmatrac: Top therapies recorded double-digit growth in May
By Gunjan Rajput and Sunil Raghu
AHMEDABAD/NEW DELHI – Eli Lilly's Mounjaro continued to maintain its position as the highest-selling pharmaceutical brand in the glucagon-like peptide-1 segment in India in May, according to Pharmatrac's Indian Pharmaceutical Market May data discussed during a webinar on Monday.
The country's anti-obesity market was valued at around INR 20 billion till May. India's pharmaceutical market recorded an 11% growth in value terms in May, with leading therapies posting a double-digit growth, said Sheetal Sapale, vice president, Commercial, Pharmatrac. The anti-obesity segment, driven largely by glucagon-like peptide-1 therapies, witnessed slower growth in May compared with April, although it continued to expand in value terms.
Semaglutide remained the key driver of growth in the glucagon-like peptide-1 market, boosted by improved affordability following the launch of generic versions in March. However, growth in semaglutide generics appeared to be stabilising, indicating that the market was moving beyond the initial generic launch-led expansion phase.
A significant portion of patients who were previously unable to access glucagon-like peptide-1 therapies due to high costs may have already entered the treatment pool, Sapale said. Sustained growth in the segment would require expansion of the eligible patient base, she added.
Despite rising competition from generics, innovator glucagon-like peptide-1 brands have remained resilient, according to Sapale. As per the Pharmatrac May report, seven of the 35 semaglutide brands marketed by 17 companies recorded an upward trend in May over April. However, with overall market growth slowing, some brands have begun showing negative traction, raising the possibility of inventory build-up in the semaglutide generics segment.
Despite signs of moderation in the overall market growth, several semaglutide brands continued to gain traction in May. Among injectable products, Novo Nordisk's Ozempic posted a 27% growth in monthly units sold, while Eris Lifesciences Ltd. Sundae grew 29%. Sun Pharmaceuticals Ltd. Noveltreat and Sematrinity recorded growth of 124% and 66%, respectively, while Alkem Laboratories Ltd. Hepaglide rose 20%. Among oral semaglutide brands, Torrent Pharmaceuticals Ltd. Semalix and Sembolic grew 19% and 32%, respectively, in April.
The research firm also noted that tirzepatide has returned to its pre-generic-launch growth trajectory, indicating continued physician preference for innovator therapies. Positive trends in innovator brands despite the influx of lower-cost generic alternatives suggest sustained confidence among specialists in evidence-based products, it said.
The research firm also gave three reasons on which the futuristic growth of the glucose-like-peptide-1 growth market will depend, such as patient sustenance, dropouts which will determine the repurchase of the medicine, new patient onboarding, and government advisories leading to stringent patient onboarding norms.
Pharmatrac data showed broad-based growth across leading pharmaceutical companies in May, with Glenmark Pharmaceuticals Ltd. posting a 16.6% value growth, USV Pvt. Ltd. 14.1%, Ipca Laboratories Ltd. 14.0%, Aristo Pharmaceuticals Pvt. Ltd. 12.0%, and GlaxoSmithKline Pharmaceuticals Ltd. 9.5%. Dr Reddy's Laboratories Ltd. and Macleods Pharmaceuticals Ltd. reported a growth of 8.0% and 8.7%, respectively, while Eris Lifesciences grew 9.2%. End
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
